ASLAN Pharmaceuticals Excels in Eblasakimab Trials

Aslan Pharmaceuticals Ltd Adr (ASLN) has released an update.

ASLAN Pharmaceuticals has reported promising interim data from its TREK-DX study, with its drug eblasakimab showing significant efficacy in atopic dermatitis patients who had previously not responded to dupilumab. The company is also progressing on two Phase 2 studies, with top-line data expected in the second half of 2024. Financially, ASLAN has seen a decrease in net loss and operating expenses compared to the previous year, alongside a successful registered direct offering.

For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.